Prilenia shares HD trial data with CHDI to help future research
Clinical trial data can drive discovery long after a study ends. Prilenia donated placebo-arm data from 2 HD clinical trials to CHDI, a valuable resource for researchers to better understand placebo effects, HD progression and future trial design. Read more
Looking back and moving forward: Questions and lessons 4 weeks out from Roche’s disappointing news
⏱️10min read | Roche’s decision to stop development of 2 HTT-lowering programmes is disappointing, but the story doesn’t end there. Years of research answered some key questions, raised many new ones, and will inform the next generation of HD trials. Read more
July 2026: This Month in Huntington’s Disease Research
⏱️ 8 min read | July was a hard month for Huntington’s disease research, with Roche ending two HD programs. But the month also brought promising new tools, a new player in somatic expansion, and important work on eating and self-awareness in HD. Read more
Putting it in print: a clinical trial trying to rein in runaway pruning
⏱️10 min read | Four years after announcing positive results in their trial of ANX005 (tanruprubart) for HD, Annexon has formally published the results. It’s safe, hits its target, and may have helped some participants – so what’s the holdup? Read more
Joining the Starting Lineup: MutLβ’s Role in DNA Repeat Expansions
⏱️8 min read | Scientists have known that MutLβ is linked to repeat expansion but not exactly how. A study reveals that the MutLβ protein complex is a main player supporting and interacting with key DNA repair proteins to drive DNA repeat expansions. Read more
Catching a Giant Protein: Five New Ways to Grab Huntingtin
⏱️8 min read | Scientists screened over a trillion tiny ring-shaped protein fragments to find ones that can grab onto the huntingtin. They captured huntingtin straight out of cells and discovered it’s almost always paired with a partner called HAP40. Read more
EN 
ES 
IT 
DE 
FR